Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Meningococcal groups A, C, W-135, and Y conjugate vaccine
- Development stage
- Approved
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
Meningococcal groups A, C, W-135, and Y conjugate vaccine is an active immunizing agent used to prevent invasive disease caused by *Neisseria meningitidis* serogroups A, C, W-135 (also called W), and Y. The vaccine contains capsular polysaccharides from these four serogroups that are chemically linked (conjugated) to a carrier protein such as diphtheria toxoid or tetanus toxoid. This conjugation enhances the immune response compared to plain polysaccharide vaccines by promoting T-cell dependent immunity and robust antibody production. Upon administration via intramuscular injection (or subcutaneous in some cases), the body produces bactericidal antibodies directed against the capsular polysaccharides of these *Neisseria* strains[1][5][7]. The primary indication is prevention of invasive meningococcal disease in children and adults.
- Brand names
- MenactraMenveoMenQuadfi
- Other names
- meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccinemeningococcal A C Y and W-135 diphtheria conjugate vaccine
02
Targets
MCV (Meningococcal capsular polysaccharides conjugated to carrier proteins)
Beyond the preview
Go deeper on Meningococcal groups A, C, W-135, and Y conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Meningococcal groups A, C, W-135, and Y conjugate vaccine.